<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02522338</url>
  </required_header>
  <id_info>
    <org_study_id>1008078</org_study_id>
    <secondary_id>2010-022272-31</secondary_id>
    <nct_id>NCT02522338</nct_id>
  </id_info>
  <brief_title>Measurement of Glomerular Filtration Rate (GFR) in HIV Patients: Single-center Study Comparing the Accuracy of Estimators of GFR Versus Iohexol Plasma Clearance</brief_title>
  <acronym>HIVOL</acronym>
  <official_title>Measurement of Glomerular Filtration Rate (GFR) in HIV Patients: Single-center Study Comparing the Accuracy of Estimators of GFR Versus Iohexol Plasma Clearance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cystatin C, a protease inhibitor produced by most nucleated cells, is freely filtered by the
      kidneys, and its plasma assay reflects the GFR.

      Compare, in HIV patients, the predictive performance of 11 formula to estimate GFR based on
      assay plasma cystatin C with that of the MDRD formulas.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient with a predictive performance range -30% to +30%</measure>
    <time_frame>day 0</time_frame>
    <description>for each estimator :predictive performance calculated by [(DFG estimé* - DFG mesuré par iohexol**)/DFG mesuré par iohexol]X100</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>iohexol plasma clearance</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>patients had received iohexol for measuring GFR</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>iohexol</intervention_name>
    <description>10 ml de l'iohexol (300 mgI/ml)</description>
    <arm_group_label>iohexol plasma clearance</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients infected with HIV, and included in the cohort NADIS

        Exclusion Criteria:

          -  Patient with a known allergy

          -  Patients treated with metformin

          -  Patients with severe hepatic impairment defined as a TP spontaneously below 50%

          -  Patients with a history of dysthyroidism

          -  Patient with active neoplasia other than skin cancer

          -  Degradation recent (not older than 3 months) in renal function defined as the
             deterioration of GFR over 25%.

          -  Estimated GFR less than 15 mL/min/1, 73m2

          -  Pregnant or lactating

          -  Subjects under the protection of justice
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frédéric LUCHT, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de SAINT-ETIENNE</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de SAINT-ETIENNE</name>
      <address>
        <city>Saint-etienne</city>
        <zip>42000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2015</study_first_submitted>
  <study_first_submitted_qc>August 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2015</study_first_posted>
  <last_update_submitted>March 9, 2016</last_update_submitted>
  <last_update_submitted_qc>March 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

